Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancerBreast Cancer 2021 Sep 07;[EPub Ahead of Print], N Taira, K Kashiwabara, J Tsurutani, M Kitada, M Takahashi, H Kato, Y Kikawa, E Sakata, Y Naito, Y Hasegawa, T Saito, T Iwasa, T Takashima, T Aihara, H Mukai, F Hara
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.